amisulpride

REMS

Prevention of postoperative nausea and vomiting (as monotherapy or in combination with another antiemetic in a different pharmacologic class).
Treatment of postoperative nausea and vomiting in patients who have received antiemetic prophylaxis with an agent of a different pharmacologic class or have not received prophylaxis.

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Hypersensitivity;
Congenital long QT syndrome.

Use Cautiously in:

Arrhythmias, conduction disorders, hypokalemia, hypomagnesemia, or HF (↑ risk of QT interval prolongation);
Concurrent use of QT interval prolonging medications (↑ risk of QT interval prolongation);
OB: Safety not established in pregnancy;
Lactation: Use while breastfeeding only when potential maternal benefit justifies potential risk to infant;
Pedi: Safety and effectiveness in children not established.

Adv. Reactions/Side Effects ⬆ ⬇

CV: hypotension (during surgical procedure), QT interval prolongation

Endo: hyperprolactinemia

F and E: hypokalemia

GI: abdominal distention

Local: pain at infusion site

Misc: chills

Interactions ⬆ ⬇

Drug-drug:

Droperidol and other QT interval prolonging medicationsmay ↑ risk of QT interval prolongation and torsades de pointes; avoid concurrent use with droperidol.
Dopamine agonists, including levodopa, may ↓ effectiveness; avoid concurrent use.

Availability ⬆ ⬇

Solution for injection: 2.5 mg/mL

Route/Dosage ⬆ ⬇

Prevention of Postoperative Nausea and Vomiting

IV (Adults ): 5 mg as a single dose administered at the time of anesthesia induction.

Treatment of Postoperative Nausea and Vomiting

IV (Adults ): 10 mg as a single dose administered at onset of nausea/vomiting following surgical procedure.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Blocks dopamine-2 and dopamine-3 receptors in chemoreceptor trigger zone of the CNS, which decreases stimulation of the vomiting center.

Therapeutic effects:

Decreased nausea and vomiting following surgical procedures.

Classifications ⬆ ⬇

Therapeutic Classification: antiemetics

Pharmacologic Classification: dopamine antagonists

Pharmacokinetics ⬆ ⬇

Absorption: IV administration results in complete bioavailability.

Distribution: Extensively distributed to tissues.

Metabolism/Excretion: Undergoes minimal metabolism. Primarily excreted in urine (74%; 58% as unchanged drug), with 23% excreted in feces (20% as unchanged drug).

Half-Life: 4–5 hr.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTE	ONSET	PEAK	DURATION
IV	unknown	end of infusion	unknown

Patient/Family Teaching ⬆ ⬇

Instruct patient to notify health care professional immediately if they perceive a change in heart rate, feel lightheaded, or faint.
Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
Rep: Advise patient to notify health care professional if pregnancy is planned or suspected. Advise breastfeeding patients to consider interrupting breastfeeding and pumping and discard breast milk for 48 hr after administration to minimize exposure to infant. May cause a reversible increase in milk production. May cause reversible infertility in females.

Pronunciation ⬆ ⬇

Code ⬆

NDC Code

51604- COSMA Spa
- 51604-1156-
  - 51604-1156-0- 40 kg in 1 DRUM (51604-1156-0)

71390- Acacia Pharma Ltd
- 71390-125- Barhemsys
  - 71390-125-20- 10 CARTON in 1 PACKAGE (71390-125-20) / 1 VIAL, SINGLE-DOSE in 1 CARTON (71390-125-21) / 2 mL in 1 VIAL, SINGLE-DOSE

71390- Acacia Pharma Ltd
- 71390-125- Barhemsys
  - 71390-125-50- 10 CARTON in 1 PACKAGE (71390-125-50) / 1 VIAL, SINGLE-DOSE in 1 CARTON (71390-125-51) / 4 mL in 1 VIAL, SINGLE-DOSE

section name header

Indications ⬇